Healthcare Triangle completes US$2 million private placement debt offering
The company received gross proceeds of approximately US$1.7 million and net proceeds,
The company received gross proceeds of approximately US$1.7 million and net proceeds,
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Dedicates upgraded National Centre for Disease Control, Delhi and a Temporary Regional Branch of NCDC to the nation
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
AMI to become part of Enpro’s Sealing Technologies Segment
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
Subscribe To Our Newsletter & Stay Updated